Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription 01.09.2025 1 Am J Respir Crit Care Med 2 Ann Surg Oncol 2 Ann Thorac Surg 4 Anticancer Res 5 BMC Cancer 1 Cancer Epidemiol Biomarkers Prev 1 Cancer Res 1 Carcinogenesis 1 Chest 1 Clin Cancer Res 12 Clin Lung Cancer 1 Eur J Cancer 2 Eur J Cardiothorac Surg 1 J Thorac Cardiovasc Surg 7 Lung Cancer 1 Oncogene 2 Oncol Rep 1 Oncologist

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Respir Crit Care Med

1. PAEZ R, Lentz RJ, Duke JD, Siemann JK, et al
   Robotic versus Electromagnetic Bronchoscopy for Peripheral Pulmonary Lesions: A Randomized Trial (RELIANT).
   Am J Respir Crit Care Med. 2025;211:1644-1651.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

2. JI Y, Cui K, Zhang J, Wang J, et al
   Noninvasive Prediction of Programmed Cell Death Protein-Ligand 1 Expression in Locally Advanced Non-small Cell Lung Cancer by (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography-Based Metabolic Habitats: A Multicenter Radiomic an
   Ann Surg Oncol. 2025 Aug 29. doi: 10.1245/s10434-025-18139.
   PubMed         Abstract available
   
   
3. YIKAI X, Jian Z, Zhenyu Y, Zhangyi D, et al
   ASO Author Reflections: Visible Pleural Retraction: An Underestimated Prognostic Marker for Early-Stage Non-Small Cell Lung Cancer.
   Ann Surg Oncol. 2025 Aug 27. doi: 10.1245/s10434-025-18226.
   PubMed        
   
   

   
   Ann Thorac Surg

4. SEYOUM N, Eaton DB Jr, Tohmasi S, Rossetti N, et al
   Adherence to Post-Operative Survivorship Quality Metrics in Early-Stage Non-Small Cell Lung Cancer.
   Ann Thorac Surg. 2025 Aug 27:S0003-4975(25)00797.
   PubMed         Abstract available
   
   
5. KAMTAM DN, Berry MF, Lin N, Kapula N, et al
   The association of chylothorax with aggressiveness of lymph node management during pulmonary resection.
   Ann Thorac Surg. 2025 Jan 31:S0003-4975(25)00086.
   PubMed         Abstract available
   
   

   
   Anticancer Res

6. AOKI M, Kamimura GO, Tsuneyoshi Y, Morizono S, et al
   Thorough Lymphadenectomy Impairs Immunotherapy Outcomes for Postoperative Intrathoracic Recurrence of Non-small Cell Lung Cancer.
   Anticancer Res. 2025;45:3971-3981.
   PubMed         Abstract available
   
   
7. FUKUI T, Hori S, Hatakeyama Y, Kiriu T, et al
   Stratification by PD-L1 TPS in Advanced NSCLC With Low PD-L1 Expression for Optimizing Immunotherapy.
   Anticancer Res. 2025;45:3859-3875.
   PubMed         Abstract available
   
   
8. GLATZEL-PLUCINSKA N, Piotrowska A, Olbromski M, Rzechonek A, et al
   EGFR Levels in NSCLC Are Associated With Expression of SATB1 and EMT-promoting Factors.
   Anticancer Res. 2025;45:3639-3660.
   PubMed         Abstract available
   
   
9. HINO H, Maru N, Utsumi T, Matsui H, et al
   Impact of Radiographical Consolidation of Tumor Size of Part-solid Adenocarcinomas on Survival - A Propensity Score-matching Analysis.
   Anticancer Res. 2025;45:3795-3807.
   PubMed         Abstract available
   
   

   
   BMC Cancer

10. YI C, Jiang S, Xiong L, Yang J, et al
    D-S-Net: an efficient dual-stage strategy for high-precision segmentation of gross tumor volumes in lung cancer CT images.
    BMC Cancer. 2025;25:1387.
    PubMed         Abstract available
    
    
11. DUDOV A, Conev N, Petrova M, Tonev I, et al
    Bulgarian exploratory analysis of time from diagnosis to treatment of lung cancer patients (Beat) - a retrospective database study on the patient pathway and time from diagnosis to treatment.
    BMC Cancer. 2025;25:1384.
    PubMed         Abstract available
    
    
12. HE X, Shi M, Zhang L, Zhan J, et al
    Baseline tumor burden predicts the efficacy of first-line chemoimmunotherapy in patients with advanced non-small cell lung cancer: results from 2 phase 3 randomized placebo-controlled trials.
    BMC Cancer. 2025;25:1380.
    PubMed        
    
    
13. FUKUI T, Imamura Y, Kakutani T, Uryu K, et al
    Real-world evidence on the survival benefit of immune checkpoint inhibitors in combination with cytotoxic chemotherapy for patients with extensive-disease small-cell lung cancer: the Tokushukai Real World Data Project (TREAD) 06.
    BMC Cancer. 2025;25:1379.
    PubMed         Abstract available
    
    
14. BAO T, Deng Y, Chen L, Sun W, et al
    Correction: Primary tumour resection in non-small cell lung cancer patients with pleural dissemination unexpectedly detected during operation: a two-centre retrospective cohort study.
    BMC Cancer. 2025;25:1398.
    PubMed        
    
    

    
    Cancer Epidemiol Biomarkers Prev

15. TAO MH, Wu T, Gordon SC, Zhou Y, et al
    Antiviral treatment Reduces Risk of Development of Lung Cancer and non-Hodgkin Lymphoma in Patients with Chronic Hepatitis C.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed         Abstract available
    
    

    
    Cancer Res

16. DING W, Zhu J, Mo J, Ouyang S, et al
    Neuropeptide Precursor VGF Promotes Neuroendocrine Differentiation and Cancer-Associated Fibroblast Activation in Small Cell Lung Cancer.
    Cancer Res. 2025 Aug 26. doi: 10.1158/0008-5472.CAN-25-0405.
    PubMed         Abstract available
    
    

    
    Carcinogenesis

17. XU S, Cai H, Wu J, Shi J, et al
    Associations of Pre-diagnostic Serum Liver Enzyme Levels with Lung Cancer Risk in Predominantly Low-income African and European Americans.
    Carcinogenesis. 2025 Aug 29:bgaf052. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Chest

18. MURGU SD, Zhou M, Laxmanan B, Wong CA, et al
    Procedure Patterns and Survival in Advanced Non-Small Cell Lung Cancer with Malignant Airway Obstruction: A SEER-Medicare Analysis.
    Chest. 2025 Aug 27:S0012-3692(25)05123-2. doi: 10.1016/j.chest.2025.07.4088.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

19. RIMNER A, Lok BH, Gelblum DY, Kotecha RR, et al
    Phase I Dose Escalation Trial Combining Olaparib and Thoracic Radiation Therapy in Extensive-Stage Small Cell Lung Cancer.
    Clin Cancer Res. 2025 Aug 29. doi: 10.1158/1078-0432.CCR-24-4342.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

20. ZENG Z, Feng S, Gao T, Chen C, et al
    Efficacy and Safety of EGFR-TKI Combined With Early Brain Radiotherapy Versus TKI Alone in Patients With EGFR-Mutated NSCLC With Brain Metastases: A Systematic Review and Meta-Analysis.
    Clin Lung Cancer. 2025;26:e391-e398.
    PubMed         Abstract available
    
    
21. GOULD MK, de Bie E, Qi L, Creekmur B, et al
    Baseline Characteristics of Participants and Pulmonary Nodules in the Watch the Spot Trial: A Pragmatic Trial of Less versus More Intensive Strategies for Active Surveillance of Patients With Small Pulmonary Nodules.
    Clin Lung Cancer. 2025;26:e472-e482.
    PubMed         Abstract available
    
    
22. FAVE T, Nguyen J, Descourt R, Quere G, et al
    Real-life Experience of Rare Hepatoid Adenocarcinomas of the Lung: A Large Retrospective French Cohort.
    Clin Lung Cancer. 2025;26:e432-e440.
    PubMed         Abstract available
    
    
23. CANTOR DJ, Nimeiri H, Horn L, West M, et al
    Outcomes Following First-Line Immune Checkpoint Inhibitors With or Without Chemotherapy Stratified by KRAS Mutational Status-A Real-World Analysis in Patients With Advanced NSCLC.
    Clin Lung Cancer. 2025;26:503-510.
    PubMed         Abstract available
    
    
24. BODOR JN, Dowell J, Treat J, Subramanian J, et al
    Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors.
    Clin Lung Cancer. 2025;26:511-514.
    PubMed         Abstract available
    
    
25. BAZZI H, Thuo N, Sravanam S, Chen W, et al
    Evaluating Diagnostic and Treatment Timelines for ALK-Positive NSCLC Patients: Results From a Global Registry.
    Clin Lung Cancer. 2025;26:470-477.
    PubMed         Abstract available
    
    
26. DE MEO ML, Seitlinger J, Rayes RF, Walsh LC, et al
    KRAS ctDNA Detection in Patients With Resectable Lung Adenocarcinoma.
    Clin Lung Cancer. 2025;26:e447-e455.
    PubMed         Abstract available
    
    
27. VUONG SQ, Liu M, Tsarovsky NW, Wudtke JD, et al
    Outcomes of Patients With Interstitial Lung Disease and Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiotherapy.
    Clin Lung Cancer. 2025 Aug 5:S1525-7304(25)00161.
    PubMed         Abstract available
    
    
28. MARAR R, Bai C, Hansen E, Zettler CM, et al
    Treatment Patterns and Outcomes of Non-Small Cell Lung Cancer with High PD-L1 Expression using Real World Evidence.
    Clin Lung Cancer. 2025 Aug 6:S1525-7304(25)00166.
    PubMed         Abstract available
    
    
29. WATANABE T, Tanahashi M, Chiba M, Hashimoto K, et al
    Postoperative Pain Reduction and Clinical Value of Uniportal Video-Assisted Thoracic Surgery: A Secondary Analysis of the J-RATSIG 01 Study.
    Clin Lung Cancer. 2025;26:e413-e419.
    PubMed         Abstract available
    
    
30. MASUDA T, Katsumata S, Isaka M, Serizawa M, et al
    Impact of TP53 Co-Mutation on Clinicopathological Features, Prognosis, Recurrence Patterns, and the Efficacy of EGFR-TKI Treatment After Recurrence in Resected Early-Stage EGFR-Mutated Lung Adenocarcinoma.
    Clin Lung Cancer. 2025;26:e374-e381.
    PubMed         Abstract available
    
    
31. SOFIANIDI AA, Syrigos NK, Blyth KG, Charpidou A, et al
    Breaking Through: Immunotherapy Innovations in Pleural Mesothelioma.
    Clin Lung Cancer. 2025;26:458-469.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

32. LINARDOU H, Papadopoulou K, Korfiatis N, Goussia A, et al
    Intercalated Avelumab plus platinum-based chemotherapy in patients with Extensive-Stage Small-Cell Lung cancer (PAVE): Final outcome, immunophenotypic and biomarker analysis of a multi-center phase II Hellenic Cooperative Oncology Group study.
    Eur J Cancer. 2025;228:115660.
    PubMed         Abstract available
    
    

    
    Eur J Cardiothorac Surg

33. KIM IH, Lee HP, Lee GD, Choi S, et al
    Wedge resection versus segmentectomy in early-stage lung cancer considering resection margin and lymph node evaluation: A retrospective study.
    Eur J Cardiothorac Surg. 2025 Aug 28:ezaf281. doi: 10.1093.
    PubMed         Abstract available
    
    
34. DAI C, Yang X, Yang D, An Z, et al
    Association Between Pathologic Response and Survival Following Neoadjuvant Targeted Therapy in Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinoma.
    Eur J Cardiothorac Surg. 2025;67:ezaf269.
    PubMed         Abstract available
    
    

    
    J Thorac Cardiovasc Surg

35. WEI M, Guo S
    Reconsidering bias and interpretation in neoadjuvant stereotactic body radiotherapy combined with immunotherapy versus standard chemoimmunotherapy for non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2025 Aug 27:S0022-5223(25)00652.
    PubMed        
    
    

    
    Lung Cancer

36. GUIJOSA A, Rios-Garcia E, Davila-Dupont D, Cruz-Rico G, et al
    Stratifying risk in oligoprogressive EGFR-mutated non-small cell lung cancer (NSCLC): The role of liquid biopsy.
    Lung Cancer. 2025;207:108722.
    PubMed         Abstract available
    
    
37. PARK Y, Kang DH, Chung C
    Integrating tumor macroenvironment, microenvironment and mechanobiology with organoid and organ-on-a-chip models for lung cancer immunotherapy.
    Lung Cancer. 2025;207:108726.
    PubMed         Abstract available
    
    
38. KUROSAKI T, Kanemura H, Otani T, Kawanaka Y, et al
    Impact of B7-H3 and DLL3 expression on the efficacy of PD-L1 blockade therapy in extensive-stage small cell lung cancer.
    Lung Cancer. 2025;207:108723.
    PubMed         Abstract available
    
    
39. SMEENK MM, van der Noort V, de Gooijer CJ, Theelen WSME, et al
    Comment on "The effectiveness of pembrolizumab maintenance with or without pemetrexed after induction treatment for advanced non-squamous Non-Small-Cell lung cancer".
    Lung Cancer. 2025;207:108725.
    PubMed        
    
    
40. TATEISHI A, Horinouchi H, Kouno N, Takeda K, et al
    Prediction recurrence in stage I epidermal growth factor receptor-mutated non-small cell lung cancer using multi-modal data.
    Lung Cancer. 2025;207:108727.
    PubMed         Abstract available
    
    
41. TAFUR A, Sebai A, Shi Z, Wei J, et al
    Polygenic risk score to define risk of cancer-associated thrombosis among patients with lung cancer in a population-based study.
    Lung Cancer. 2025;207:108712.
    PubMed         Abstract available
    
    
42. SHIJUBOU N, Sumi T, Ishigooka T, Naraoka T, et al
    Early pseudo-progression of brain metastases following tarlatamab therapy in relapsed small cell lung cancer.
    Lung Cancer. 2025;207:108730.
    PubMed        
    
    

    
    Oncogene

43. ZHOU Y, Wang H, Tang S, He Y, et al
    Identification of RAPGEF3 as the therapeutic vulnerability of basal-subtype lung squamous cell carcinoma.
    Oncogene. 2025;44:3142-3148.
    PubMed         Abstract available
    
    

    
    Oncol Rep

44. WU X, Qu C, Ouyang Y, Yang L, et al
    T cell exhaustion?related gene CD79B predicts prognosis, inhibits malignant progression and promotes tumor?associated macrophage M1?like polarization in lung adenocarcinoma.
    Oncol Rep. 2025;54:144.
    PubMed         Abstract available
    
    
45. TANG C, Hahm E, Bae S, Kang JS, et al
    [Expression of Concern] Src homology phosphotyrosyl phosphatase 2 mediates cisplatin?related drug resistance by inhibiting apoptosis and activating the Ras/PI3K/Akt1/survivin pathway in lung cancer cells.
    Oncol Rep. 2025;54:146.
    PubMed         Abstract available
    
    

    
    Oncologist

46. CHAE YK, Oh Y, Kim L, Park JH, et al
    Bilateral orthotopic lung transplantation for the patient with lung-limited invasive mucinous adenocarcinoma: a case-based literature review.
    Oncologist. 2025;30:oyae263.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.